Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Schölmerich J, Burger HU, Verweij J. Van Cutsem E, et al. Among authors: twelves c. J Clin Oncol. 2000 Mar;18(6):1337-45. doi: 10.1200/JCO.2000.18.6.1337. J Clin Oncol. 2000. PMID: 10715306 Clinical Trial.
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.
Scott L, Soepenberg O, Verweij J, de Jonge MJ, Th Planting AS, McGovern D, Principe P, Obach R, Twelves C. Scott L, et al. Among authors: twelves c. Ann Oncol. 2007 Mar;18(3):569-75. doi: 10.1093/annonc/mdl439. Ann Oncol. 2007. PMID: 17322542 Free article. Clinical Trial.
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J. Vasey PA, et al. Among authors: twelves c. Clin Cancer Res. 1999 Jan;5(1):83-94. Clin Cancer Res. 1999. PMID: 9918206 Clinical Trial.
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell D, Banken L, Goggin T, Jones D, Roos B, Bush E, Weidekamm E, Reigner B. Cassidy J, et al. Among authors: twelves c. Cancer Chemother Pharmacol. 1999;44(6):453-60. doi: 10.1007/s002800051118. Cancer Chemother Pharmacol. 1999. PMID: 10550565 Clinical Trial.
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P; Xeloda Colorectal Cancer Study Group. Van Cutsem E, et al. Among authors: twelves c. J Clin Oncol. 2001 Nov 1;19(21):4097-106. doi: 10.1200/JCO.2001.19.21.4097. J Clin Oncol. 2001. PMID: 11689577 Clinical Trial.
309 results